Dempster DW, et al. - This work sought to delineate the early effects of an established anabolic (teriparatide) versus antiresorptive (denosumab) agent on remodeling-based formation (RBF), modeling-based formation (MBF), and overflow MBF (oMBF) in human transiliac bone biopsies. Findings underscored the mechanistic differences between these agents: all 3 types of bone formation increased significantly with teriparatide while formation was predominantly decreased or not significantly changed with denosumab, except for a slight increase in MBF/BS in the cancellous envelope.